BN Business News
Add your company to Business Communicator →

Konkurencja i konsument · 17.04.1996

Hoechst AG; Prohibited Trade Practices, and Affirmative Corrective Actions

This consent order settles alleged violations of federal law prohibiting unfair or deceptive acts or practices and unfair methods of competition arising from the $7.1 billion merger of Hoechst AG and Marion Merrell Dow, Inc. The consent order, among other things, requires Hoechst--a pharmaceutical firm--to provide Biovail Corporation International with a letter of access to the toxicology data necessary to secure additional FDA approvals for a hypertension and cardiac drug called Tiazac (diltiazem). It also requires Hoechst to return any confidential information obtained from Biovail; to refrain from using the information; to dismiss a patent infringement lawsuit filed by Marion Merrell Dow regarding Tiazac; to withdraw a citizen petition Marion Merrell Dow filed with the Food and Drug Administration relating to Tiazac; and to agree not to file any subsequent litigation against Biovail regarding diltiazem. In addition, the consent order requires Hoechst to divest the rights to either Trental or Beraprost (two drugs intended to treat intermittent claudication, a painful leg cramping condition); to divest the rights to Pentasa (or the generic formulation), which is one of two oral fo

Source: Federal Register — Federal Trade CommissionOpen original release →